XML 18 R1.htm IDEA: XBRL DOCUMENT v3.25.0.1
Document And Entity Information - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Feb. 28, 2025
Jun. 28, 2024
Document Document And Entity Information [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Dec. 31, 2024    
Document Fiscal Year Focus 2024    
Entity File Number 001-39273    
Entity Registrant Name Lyra Therapeutics, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 84-1700838    
Entity Address, Address Line One 480 Arsenal Way    
Entity Address, City or Town Watertown    
Entity Address, State or Province MA    
Entity Address, Postal Zip Code 02472    
City Area Code 617    
Local Phone Number 393-4600    
Title of 12(b) Security Common Stock, $0.001 par value per share    
Trading Symbol LYRA    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period false    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 13,803,194
Entity Common Stock, Shares Outstanding   65,880,561  
Documents Incorporated by Reference

None.

    
Current Fiscal Year End Date --12-31    
Amendment Flag false    
Entity Central Index Key 0001327273    
Document Fiscal Period Focus FY    
Auditor Name BDO USA, P.C.    
Auditor Location Boston, Massachusetts    
Auditor Firm ID 243    
Auditor Opinion [Text Block]

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Lyra Therapeutics, Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations and comprehensive loss, stockholders’ equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.